EGFR and non-small cell lung carcinoma: BI-1482694) (52) is an orally effective small molecule with potential antitumor activity as a mutation-selective third-generation EGFR inhibitor developed by Hanmi Pharmaceutical Co Ltd for the treatment of NSCLC and lung adenocarcinoma.